Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -47.98% is 40% below its 5-year average of -34.21%, near the low end of its 5-year range (-54.91%–-8.71%).
54.03% below its 12-month average of -31.15%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.64%.
RETURN ON ASSETS (ROA)
-47.98%
RETURN ON ASSETS (ROA) AVG TTM
-31.15%
RETURN ON ASSETS (ROA) AVG 3Y
-42.27%
RETURN ON ASSETS (ROA) AVG 5Y
-34.21%
RETURN ON ASSETS (ROA) AVG 10Y
-50.79%
RETURN ON ASSETS (ROA) AVG 15Y
-70.31%
RETURN ON ASSETS (ROA) AVG 20Y
-82.70%
CURRENT VS TTM AVG
-54.03%
CURRENT VS 3Y AVG
-13.49%
CURRENT VS 5Y AVG
-40.27%
CURRENT VS 10Y AVG
+5.53%
CURRENT VS 15Y AVG
+31.76%
CURRENT VS 20Y AVG
+41.98%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-48.82%
vs the sector median at left
Cytosorbents Corporation
Market Cap
$12.62M
Return on Assets (ROA)
-47.98%
TTM Avg
-31.15%
3Y Avg
-42.27%
5Y Avg
-34.21%
Market Cap
$12.47M
Return on Assets (ROA)
-49.12%
TTM Avg
-29.80%
3Y Avg
-67.98%
5Y Avg
-117.36%
Market Cap
$12.46M
Return on Assets (ROA)
-60.93%
TTM Avg
-160.25%
3Y Avg
-205.49%
5Y Avg
-152.09%
Market Cap
$12.77M
Return on Assets (ROA)
-143.44%
TTM Avg
-68.17%
3Y Avg
-65.00%
5Y Avg
-57.74%
Market Cap
$12.43M
Return on Assets (ROA)
-420.14%
TTM Avg
-127.99%
3Y Avg
-97.65%
5Y Avg
-85.48%
Market Cap
$12.25M
Return on Assets (ROA)
-216.84%
TTM Avg
-118.20%
3Y Avg
-6127.40%
5Y Avg
-4092.56%
Market Cap
$12.17M
Return on Assets (ROA)
-77.94%
TTM Avg
-178.68%
3Y Avg
-1009.31%
5Y Avg
-2782.57%
Market Cap
$12.03M
Return on Assets (ROA)
-13.01%
TTM Avg
-15.22%
3Y Avg
-24.53%
5Y Avg
-20.43%
Market Cap
$13.33M
Return on Assets (ROA)
-85.85%
TTM Avg
-102.78%
3Y Avg
-95.22%
5Y Avg
-76.09%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cytosorbents Corporation (CTSO) | $12.62M | -47.98% | -31.15% | -42.27% | -34.21% |
| Dare Bioscience, Inc. (DARE)vs › | $12.47M | -49.12% | -29.80% | -67.98% | -117.36% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.46M | -60.93% | -160.25% | -205.49% | -152.09% |
| Passage Bio, Inc. (PASG)vs › | $12.77M | -143.44% | -68.17% | -65.00% | -57.74% |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.43M | -420.14% | -127.99% | -97.65% | -85.48% |
| Lantern Pharma Inc. (LTRN)vs › | $12.25M | -216.84% | -118.20% | -6127.40% | -4092.56% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.17M | -77.94% | -178.68% | -1009.31% | -2782.57% |
| IRIDEX Corporation (IRIX)vs › | $12.03M | -13.01% | -15.22% | -24.53% | -20.43% |
| IN8bio, Inc. (INAB)vs › | $13.33M | -85.85% | -102.78% | -95.22% | -76.09% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.37M | -32.53% | -31.07% | -30.77% | -29.89% |
ROA
-48.0%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -18.56% |
| 2024-12-31 | -43.74% |
| 2023-12-31 | -54.91% |
| 2022-12-31 | -51.89% |
| 2021-12-31 | -27.43% |
| 2020-12-31 | -8.71% |
| 2019-12-31 | -70.36% |
| 2018-12-31 | -52.56% |
| 2017-12-31 | -35.10% |
| 2016-12-31 | -123.16% |
| 2015-12-31 | -72.25% |
| 2014-12-31 | -110.06% |
| 2013-12-31 | -115.62% |
| 2012-12-31 | -109.71% |
| 2011-12-31 | -258.26% |
| 2010-12-31 | -160.54% |
| 2009-12-31 | -122.26% |
| 2008-12-31 | -89.10% |
| 2007-12-31 | -417.50% |
| 2006-12-31 | -222.68% |
| 2005-12-31 | -420.12% |
